Abstract: The present invention provides animal model of chronic stress diseases produced by feeding lysine deficient diet to the animals and a method for producing the animal model. The effect of medicine on chronic stress diseases can be judged with the animal model. Effective compounds in preventing chronic stress diseases and/or treating patients suffering from chronic stress diseases can be screened by using the animal model.

Abstract: An agonist or antagonist of glutamic acid or an allosteric modulator is screened by reacting a glutamic acid receptor protein having the following properties with a substance binding thereto in the presence of a test substance and detecting the inhibition or promotion of the reaction: (A) it has a transmembrane domain and an intracellular domain common to those of type 4 metabotropic glutamic acid receptor protein, or (B) it has an extracellular domain by about 316 or 327 amino acid residues shorter than that of the type 4 metabotropic glutamic acid receptor protein.

Abstract: The present invention relates to an agent for treating and/or preventing stress-induced diseases, and a pharmaceutical composition (pharmaceutical product), a food, drink, or a feed containing the same. More specifically, the present invention relates to an agent (pharmaceutical drug) containing lysine as the active (effective) ingredient, and a pharmaceutical product, a food, a drink, or a feed containing the agent (pharmaceutical drug). Furthermore, the present invention relates to a method for suppressing stress, and a method for the therapeutic treatment, amelioration and/or prevention of stress-induced diseases, as well as a use of lysine for anti-stress agents or stress suppressor.

Abstract: A method and an apparatus for peeling cells from a vital tissue by applying vibration to a part of the vital tissue. The method and apparatus for peeling cells close to in-vivo cells applies vibration to a part of a vital tissue. Accordingly, the use of the cells peeled by the method and apparatus is quite effective for clarifying a biological structure, developing medications, and the like.

Abstract: Melatonin has an activity of treating or preventing brain edema. Thus, the invention relates to a pharmaceutical composition comprising melatonin as an active ingredient. And, the invention relates to use of melatonin in the preparation of a pharmaceutical composition comprising melatonin as an active ingredient.

Abstract: Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc.

Abstract: Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel such as encephalopathies caused by the ischemia in the acute phase after the onset of cerebral infarction, cerebral hemorrhage or the like, Alzheimer's disease, etc.

Abstract: Dihydropyridine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel. They are used as remedies for various diseases relating to the N-type calcium channel.

Abstract: The administration of a therapeutically effective amount of melatonin is an effective method for treating paralysis of the extremities caused by cerebral infarction.

Abstract: The administration of a therapeutically effective amount of melatonin is an effective method for treating paralysis of the extremities caused by cerebral infarction.